Cancer

Endometrial cancer is the second most common gynecologic cancer worldwide, and researchers continue to search for ways to reduce the risk of recurrence after initial treatment. While significant progress has been made in advanced disease, preventing cancer from returning remains a major challenge.

A new phase 3 clinical trial known as DESTINY-Endometrial02 is evaluating whether ENHERTU (trastuzumab deruxtecan) can help patients with HER2-expressing endometrial cancer when used earlier in treatment. The study reflects growing interest in bringing targeted therapies into earlier stages of care, where they may have the greatest impact.

Hormone receptor-positive, HER2-negative breast cancer is the most common subtype of breast cancer. While treatments have improved significantly over the years, many patients eventually develop resistance to standard therapies, allowing cancer to continue growing despite treatment.

Researchers have increasingly focused on a pathway known as PI3K/AKT/mTOR/PTEN, which plays a critical role in cancer growth and survival. New therapies targeting this pathway are creating additional treatment options and helping move breast cancer care toward a more personalized future.

Not all endometrial cancers behave the same way. Some tumors are treated successfully and never return, while others come back despite appearing low-risk when first diagnosed. This has led researchers to look beyond traditional pathology and focus on the genetic changes that may influence how a cancer behaves.

One gene receiving increasing attention is CTNNB1. Recent research suggests that mutations in this gene may help identify patients who face a higher risk of recurrence, even when their cancer appears less aggressive under a microscope. As precision medicine continues to advance, CTNNB1 could become an important tool for improving treatment decisions and patient outcomes.

Prostate cancer is one of the most common cancers affecting men worldwide. In many cases, it grows slowly and may not cause symptoms for years. However, some forms can be aggressive and spread beyond the prostate, making early detection and appropriate treatment extremely important.

Researchers continue to learn more about the genetic and biological factors that drive prostate cancer, leading to improved screening methods and more personalized treatment options. A comprehensive review of prostate cancer research highlights how advances in genetics, diagnosis, and treatment are helping improve outcomes while reducing unnecessary treatment for low-risk disease.